Conference Coverage
Conference Coverage
High-risk B-ALL subgroup has ‘outstanding outcomes’
Photo courtesy of ASH ORLANDO, FL—A subgroup of young patients with high-risk B-cell acute lymphoblastic leukemia (B-ALL) can have “outstanding...
Conference Coverage
BM fibrosis grade may impact OS in PMF
ORLANDO, FL—Having a higher grade of bone marrow (BM) fibrosis may confer inferior overall survival (OS) in patients with primary myelofibrosis (...
Conference Coverage
EZH2 inhibitor can produce durable responses
ORLANDO, FL—Updated results of a phase 1 study suggest the EZH2 inhibitor tazemetostat (EPZ-6438) can produce durable responses in patients with...
Conference Coverage
Combo deepens responses and improves PFS in MM
Photo courtesy of the University of Navarra ORLANDO, FL—The addition of panobinostat to bortezomib-dexamethasone therapy in relapsed or...
Conference Coverage
Frailty in HSCT population not dependent on age
Photo by Peter Griffin ORLANDO, FL—Frailty after hematopoietic stem cell transplant (HSCT), while associated with higher mortality, is not...
Conference Coverage
Heavily pretreated myeloma responds to pembrolizumab combo
Key clinical point: Initial results show promising activity for pembrolizumab in combination with lenalidomide and low-dose dexamethasone in...
Conference Coverage
Statin may reduce vaso-occlusive pain in SCD
Photo courtesy of the CDC ORLANDO, FL—In a small study, the cholesterol-lowering medication simvastatin reduced the frequency of vaso-occlusive...
Conference Coverage
VIDEO: Dr. Hope S. Rugo discusses immunotherapy, neoadjuvant treatment highlights
Dr. Hope S. Rugo shared her insights on breast cancer research presented at the San Antonio Breast Cancer Symposium.
Conference Coverage
T-DM1 trial points way to de-escalation of breast cancer therapy
Key clinical point: T-DM1 as neoadjuvant monotherapy enables selected breast cancer patients to avoid neoadjuvant chemotherapy and/or endocrine...
Conference Coverage
Potential new alternative in CML when TKI therapy fails
ASH Annual Meeting Photo courtesy of ASH ORLANDO, FL—ABL001, an allosteric inhibitor of BCR-ABL1, has shown early evidence of single-agent...